erlotinib has been researched along with akt-i-1,2 compound in 1 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (akt-i-1,2 compound) | Trials (akt-i-1,2 compound) | Recent Studies (post-2010) (akt-i-1,2 compound) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 56 | 0 | 34 |
| Protein | Taxonomy | erlotinib (IC50) | akt-i-1,2 compound (IC50) |
|---|---|---|---|
| Low molecular weight phosphotyrosine protein phosphatase | Homo sapiens (human) | 7.43 | |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | 0.2748 | |
| RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | 0.5861 | |
| RAC-gamma serine/threonine-protein kinase | Homo sapiens (human) | 1.4843 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R | 1 |
1 review(s) available for erlotinib and akt-i-1,2 compound
| Article | Year |
|---|---|
Selectively nonselective kinase inhibition: striking the right balance.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Humans; Protein Binding; Protein Kinase Inhibitors; Structure-Activity Relationship | 2010 |